Follow-on Biologics: As Mark-Ups Loom, What's Waxman's End Game?
Executive Summary
Coming to an abrupt halt after racing at full speed is never easy, but that seems to be the best play available to generic advocates of a legislative pathway for follow-on biologics
You may also be interested in...
The Shadow Of 2003: Hatch/Waxman Changes May Join Health Reform Bills
The Medicare drug benefit, created in 2003, is casting a long shadow on the health care reform debate of 2009
The Shadow Of 2003: Hatch/Waxman Changes May Join Health Reform Bills
The Medicare drug benefit, created in 2003, is casting a long shadow on the health care reform debate of 2009
Orphan Biologics Should Get Two Extra Years Of Exclusivity, NORD Says
Organization tells Rep. Waxman it still "wholeheartedly" supports his bill, but is planning its legislative approach around longer brand exclusivity.